Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study

Geisler, Jürgen, Haynes, Ben, Anker, Gun, Dowsett, Mitch, Lønning, Per Eystein·2002·Journal of Clinical Oncology
DOI 10.1200/jco.20.3.751

Cited by (606)

Items 201–300 of 606

  1. Letrozole vs Anastrozole for Height Augmentation in Short Pubertal Males: First Year Data
    E. Kirk Neely, Rajiv B Kumar, Sydney L. Payne, Sayali A. Ranadive, Diane I. Suchet · 2014 · The Journal of Clinical Endocrinology & Metabolism
  2. Mammographic Breast Density Response to Aromatase Inhibition
    Celine M. Vachon, Vera Jean Suman, Kathleen R. Brandt, Matthew Kosel, Aman U. Buzdar, Janet E. Olson, Fang-Fang Wu, Lynn M. Flickinger, Giske Ursin, Catherine Elliott et al. · 2013 · Clinical Cancer Research
  3. Cancer of the Breast
    Norah Lynn Henry, Payal Deepak Shah, Irfanullah Haider, Phoebe E. Freer, Reshma Jagsi, Michael S. Sabel · 2020 · Elsevier eBooks
  4. RETRACTED: Clomiphene citrate or anastrozole for ovulation induction in women with polycystic ovary syndrome? A prospective controlled trial
    Ahmed Badawy, Ibrahim Abdel Aal, Mohamed Abulatta · 2008 · Fertility and Sterility · Retracted
  5. Effect of Estrogen Depletion on Pain Sensitivity in Aromatase Inhibitor–Treated Women With Early-Stage Breast Cancer
    Norah Lynn Henry, Anna Conlon, KM Kidwell, Kent A. Griffith, Jeffrey B. Smerage, Anne F. Schott, Daniel F. Hayes, David A. Williams, Daniel Joseph Clauw, Steven E. Harte · 2014 · Journal of Pain
  6. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients
    J. Baumgart, K. Nilsson, Anneli C. Stavreus-Evers, Theodora Kunovac Kallak, Mark M. Kushnir, Jonas Bergquist, Inger Sundström Poromaa · 2013 · Climacteric
  7. Short-term aromatase inhibition: effects on glucose metabolism and serum leptin levels in young and elderly men
    Bruno Lapauw, Guy G. T'Sjoen, A. Mahmoud, Jean‐Marc Kaufman, Johannes B Ruige · 2008 · European Journal of Endocrinology
  8. Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers
    Adrienne E. Borrie, Richard B. Kim · 2016 · Expert Opinion on Drug Metabolism & Toxicology
  9. The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature
    Nadeen Anabtawi, Thomas Drabison, Shuiying Hu, Alex Sparreboom, Zahra Talebi · 2022 · Expert Opinion on Drug Metabolism & Toxicology
  10. A Pilot Study Comparing the Effect of Flaxseed, Aromatase Inhibitor, and the Combination on Breast Tumor Biomarkers
    Susan E. McCann, Stephen B. Edge, David G. Hicks, Lilian U. Thompson, Carl D. Morrison, Gerald J. Fetterly, Chris Andrews, Kim Clark, John H. Wilton, Swati Kulkarni · 2014 · Nutrition and Cancer
  11. Prevention and treatment of bone fragility in cancer patient
    Silva Ottanelli · 2015 · Clinical cases in mineral and bone metabolism
  12. Letrozole
    Lesley J. Scott, Susan J. Keam · 2006 · Drugs
  13. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
    Sandra J. Lewis · 2007 · American Heart Journal
  14. Are all aromatase inhibitors the same? A review of the current evidence
    Fritz Jänicke · 2004 · The Breast
  15. Breast cancer: Aromatase inhibitors take on tamoxifen
    Mitch Dowsett, Anthony Howell · 2002 · Nature Medicine
  16. Clinical Studies Examining the Impact of Obesity on Breast Cancer Risk and Prognosis
    Rishi Jain, Howard D. Strickler, Eugene J. Fine, Joseph A. Sparano · 2013 · Journal of Mammary Gland Biology and Neoplasia
  17. Are aromatase inhibitors superior to antiestrogens?
    Anthony Howell, Aman U. Buzdar · 2005 · The Journal of Steroid Biochemistry and Molecular Biology
  18. Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results
    Shunji Takahashi, Takuji Iwase, Norio Kohno, Takashi Ishikawa, Tetsuya Taguchi, Masato Takahashi, Jun Horiguchi, Seigo Nakamura, Yasuo Hozumi, Masao Fukunaga et al. · 2012 · Breast Cancer Research and Treatment
  19. Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy
    Manfred Kaufmann, Achim Rody · 2005 · Journal of Cancer Research and Clinical Oncology
  20. Pharmacogenetics of anti-estrogen treatment of breast cancer
    Marzia Del Re, Angela Michelucci, Paolo Simi, Romano Danesi · 2011 · Cancer Treatment Reviews
  21. Aromatase inhibitors for therapy of advanced breast cancer
    James N. Ingle, Vera Jean Suman · 2005 · The Journal of Steroid Biochemistry and Molecular Biology
  22. Anti-tumor Effects of Letrozole
    William R. Miller, Thomas James Anderson, J. Michael Dixon · 2002 · Cancer Investigation
  23. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer
    TA Traina, Italo Poggesi, Mark E. Robson, Aviva G. Asnis, B. A. Duncan, Alexandra Simkovich Heerdt, Chau T. Dang, Diana E. Lake, Mark M. Moasser, Katherine S. Panageas et al. · 2007 · Breast Cancer Research and Treatment
  24. «Cancers du sein»
    Saint-Paul-de-Vence, Promoteur: Cours de Saint-Paul-de-Vence, Organisation: LOb Conseils, Joseph Gligorov · 2005 · ONCOLOGIE
  25. Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data
    Aman U. Buzdar, Jack M. Cuzick · 2006 · Clinical Cancer Research
  26. Impact of aromatase inhibitors on bone health in breast cancer patients
    Jürgen Geisler, Per Eystein Lønning · 2009 · The Journal of Steroid Biochemistry and Molecular Biology
  27. Preventing Relapse Beyond 5 Years: The MA.17 Extended Adjuvant Trial
    Paul Edward Goss · 2006 · Seminars in Oncology
  28. Sex-steroidal regulation of aromatase mRNA expression in adult male rat brain: a quantitative non-radioactive in situ hybridization study
    Changjiu Zhao, Ryutaro Fujinaga, Akie Yanai, Keiji Kokubu, Yukio Takeshita, Yoshifumi Watanabe, Koh Shinoda · 2008 · Cell and Tissue Research
  29. Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen
    Celine M. Vachon, James N. Ingle, Vera Jean Suman, Christopher G. Scott, H. Gottardt, Janet E. Olson, Paul Edward Goss · 2006 · The Breast
  30. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats
    Jürg Andreas Gasser, Jonathan R. Green, Victor Shen, Peter Ingold, A. Rebmann, Ajay S. Bhatnagar, Dean B. Evans · 2006 · Bone
  31. Cardiovascular Safety Profiles of Aromatase Inhibitors
    Jean‐Marc Nabholtz, Joseph Gligorov · 2006 · Drug Safety
  32. Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone
    Maria Gabriella Jannuzzo, Enrico di Salle, Riccardo Spinelli, Nicoletta Pirotta, Peter Buchan, Akintunde Bello · 2008 · Breast Cancer Research and Treatment
  33. Safety of aromatase inhibitor therapy in breast cancer
    Anneleen Lintermans, Patrick Neven · 2015 · Expert Opinion on Drug Safety
  34. Cognitive effects of aromatase inhibitor therapy in peripubertal boys
    Hero, M, Maury, S, Luotoniemi, E, Service, E, Dunkel, L · 2010 · European Journal of Endocrinology
  35. Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin–estrogen receptor loop signaling
    Sheng‐Fan Wang, Yuh-Lih Chang, Yen‐Dun Tony Tzeng, Chun-Ling Wu, Yuan-Zhong Wang, Ling‐Ming Tseng, Shiuan Chen, Hsin‐Chen Lee · 2021 · Cancer Letters
  36. Safety of aromatase inhibitors in the adjuvant setting
    Edith A. Perez · 2007 · Breast Cancer Research and Treatment
  37. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women
    Juliette Murray, O. E. Young, Lorna Renshaw, Stephen L. White, Linda Jane Williams, Dean B. Evans, James Thomas, Mitch Dowsett, J. Michael Dixon · 2008 · Breast Cancer Research and Treatment
  38. Clinical Use of Aromatase Inhibitors in Adult Males
    Ronny Tan, André T. Guay, Wayne J.G. Hellstrom · 2014 · Sexual Medicine Reviews
  39. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment
    J. Michael Dixon · 2002 · Expert Review of Anticancer Therapy
  40. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden
    Jonas Lundkvist, Nils Erik Wilking, Stig B. Holmberg, Linus Jönsson · 2006 · Breast Cancer Research and Treatment
  41. Future Directions in the Treatment of Hormone-Sensitive Advanced Breast Cancer: The RAD001 (Everolimus)-Letrozole Clinical Program
    Heidi A. Lane, David Lebwohl · 2006 · Seminars in Oncology
  42. Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy
    Rowan T. Chlebowski, Jung Ah Kim, Nananda F. Col · 2003 · Seminars in Oncology
  43. Aromatase Inhibitor-Associated Bone Loss
    Shubham Pant, Charles L. Shapiro · 2008 · Drugs
  44. Therapeutic uses of aromatase inhibitors in men
    de Ronde, Willem · 2007 · Current Opinion in Endocrinology, Diabetes & Obesity
  45. Serum Soluble Epidermal Growth Factor Receptor Concentrations Decrease in Postmenopausal Metastatic Breast Cancer Patients Treated with Letrozole
    Jacqueline M. Lafky, Andre T. Baron, Elsa M. Cora, David W. Hillman, Vera Jean Suman, Edith A. Perez, James N. Ingle, Nita J. Maihle · 2005 · Cancer Research
  46. New developments in the treatment of postmenopausal breast cancer
    Anthony Howell · 2005 · Trends in Endocrinology and Metabolism
  47. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index
    Mehmet Alı Nahıt Şendur, Sercan Aksoy, Nurullah Zengin, Kadri Altundağ · 2012 · British Journal of Cancer
  48. Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
    Martina Bauer, Jane Bryce, Hadji · 2012 · Breast Cancer Targets and Therapy
  49. Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole
    Tatiana Michelle Prowell, Amanda L. Blackford, Celia Byrne, Nagi F. Khouri, Mitch Dowsett, Elizabeth J. Folkerd, Karineh Tarpinian, Pendleton P. Powers, Laurie A. Wright, Michele G. Donehower et al. · 2011 · Cancer Prevention Research
  50. Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors
    Tilman D. Rachner, Andy Göbel, Nikolai Jaschke, Lorenz Christian Hofbauer · 2020 · The Journal of Clinical Endocrinology & Metabolism
  51. Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event
    Nikolaos Mitsimponas, E. Klouva, Dimitrios J. Tryfonopoulos, Anastasios Grivas, Stamatina G Demiri, George Koumakis, Panagiotis Gouveris · 2018 · Case Reports in Oncology
  52. Evolution of Medical Approaches and Prominent Therapies in Breast Cancer
    Suzann Duan, Iain L. O. Buxton · 2022 · Cancers
  53. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability
    J. Michael Dixon, Lorna Renshaw, C. Langridge, Oliver Young, Mary McHugh, Linda Jane Williams, Juliette Murray, E. Jane Macaskill, Fiona McCaig, Oliver M. Dixon et al. · 2010 · Breast Cancer Research and Treatment
  54. Endocrine therapy of breast cancer
    Aron Goldhirsch, Marco Angelo Colleoni, Richard D. Gelber · 2002 · Annals of Oncology
  55. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort
    María Rodríguez-Sanz, Marta Pineda‐Moncusí, Sònia Servitja, Natalia García‐Giralt, Tamara Martos, Ignasi Tusquets, Martínez-García Maria, Jaime Rodríguez‐Morera, Adolfo Díez‐Pérez, Joan Albanell et al. · 2016 · Bone
  56. The Importance of CYP19A1 in Estrogen Receptor-Positive Cholangiocarcinoma
    Waleeporn Kaewlert, Chadamas Sakonsinsiri, Nisana Namwat, Kanlayanee Sawanyawisuth, Piti Ungarreevittaya, Narong Khuntikeo, Napat Armartmuntree, Raynoo Thanan · 2018 · Hormones and Cancer
  57. Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study
    Xue Lian Wang, Anjie Zhu, Jiayu Wang, Fei Ma, Jing Liu, Ying Fan, Yang Luo, Pin Zhang, Qing Li, Binghe Xu et al. · 2020 · Therapeutic Advances in Medical Oncology
  58. A prospective randomized trial comparing anastrozole and clomiphene citrate in an ovulation induction protocol using gonadotropins
    Christopher S. Sipe, William A. Davis, Michelle Maifeld, Bradley J. Van Voorhis · 2006 · Fertility and Sterility
  59. Strategies for Maximizing Growth in Puberty in Children with Short Stature
    Nelly Mauras · 2009 · Endocrinology and Metabolism Clinics of North America
  60. The current status of aromatase inhibitors in the management of breast cancer
    Michael Baum, Aman U. Buzdar · 2003 · Surgical Clinics of North America
  61. Genetic Influences in Breast Cancer Drug Resistance
    Adhitiya Daniyal, Ivana Santoso, Nadira Hasna Putri Gunawan, Melisa Intan Barliana, Rizky Abdulah · 2021 · Breast Cancer Targets and Therapy
  62. The bone–muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health
    Tarah Jean Ballinger, William R. Thompson, Theresa A. Guise · 2022 · Breast Cancer Research
  63. Strategies for Maximizing Growth in Puberty in Children with Short Stature
    Nelly Mauras · 2011 · Pediatric Clinics of North America
  64. Exemestane as First-Line Therapy in Postmenopausal Women With Recurrent or Metastatic Breast Cancer
    Stefan Glück · 2010 · American Journal of Clinical Oncology
  65. Aromatase inhibitors as adjuvant treatment of breast cancer
    Jürgen Geisler, Per Eystein Lønning · 2005 · Critical Reviews in Oncology/Hematology
  66. An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer
    Agustí Barnadas, Laura García‐Estévez, A. Lluch-Hernández, Álvaro Rodríguez-Lescure, César Rodriguez-Sanchez, Pedro Sánchez‐Rovira · 2011 · Advances in Therapy
  67. Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression
    Per Eystein Lønning, Jürgen Geisler · 2007 · The Journal of Steroid Biochemistry and Molecular Biology
  68. New steroidal aromatase inhibitors: Suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death
    Margarida Cepa, Georgina Correia‐da‐Silva, E. J. Tavares da Silva, Fernanda M.F. Roleira, Margarida Coutinho Borges, Natércia A. A. Teixeira · 2008 · BMC Cell Biology
  69. Clinical utility of exemestane in the treatment of breast cancer
    Filippo Montemurro, G Zucchini, Elena Geuna, Andrea Milani, Caterina Aversa, Rossella Martinello · 2015 · International Journal of Women s Health
  70. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen
    Ikuko Kijima, Tôru Itoh, Shiuan Chen · 2005 · The Journal of Steroid Biochemistry and Molecular Biology
  71. Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
    Cesar Augusto Santa-Maria, Amanda L. Blackford, Anne Nguyen, Todd C. Skaar, Santosh Philips, Steffi Oesterreich, James Michael Rae, Zeruesenay Desta, Jason Robarge, Norah Lynn Henry et al. · 2015 · Clinical Cancer Research
  72. Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons
    Jason Robarge, Djane Braz Duarte, Behzad Shariati, Ruizhong Wang, David Alastair Flockhart, Michael R. Vasko · 2016 · Experimental Neurology
  73. Aromatase inhibitors in advanced breast cancer
    Henning T. Mouridsen · 2004 · Seminars in Oncology
  74. Anti-oestrogenic chemoprevention of breast cancer—the need to progress
    Trevor J. Powles · 2003 · European Journal of Cancer
  75. Bone Health in Women with Early-Stage Breast Cancer
    Rowan T. Chlebowski · 2005 · Clinical Breast Cancer
  76. Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
    Αngeliki Andrikopoulou, Oraianthi Fiste, Michalis Liontos, Meletios Athanasios Dimopoulos, Flora Zagouri · 2021 · Cancers
  77. Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial
    Rowan T. Chlebowski, Dominic J. Cirillo, Charles B. Eaton, Marcia L. Stefanick, Mary B. Pettinger, Laura D. Carbone, Karen Johnson, Michael Steven Simon, Nancy Fugate Woods, Jean Wactawski‐Wende · 2018 · Menopause The Journal of The North American Menopause Society
  78. Bone Health History in Breast Cancer Patients on Aromatase Inhibitors
    Marilyn L. Kwan, Joan Chia-Mei Lo, Li Tang, Cecile A. Laurent, Janise M. Roh, Malini Chandra, Theresa Hahn, Chi‐Chen Hong, Lara E. Sucheston‐Campbell, Dawn L. Hershman et al. · 2014 · PLoS ONE
  79. Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators
    Per Eystein Lønning · 2003 · Clinical Pharmacokinetics
  80. Aromatase inhibitors—Gene discovery
    William R. Miller, Alexey A. Larionov, Lorna Renshaw, Thomas James Anderson, Sharon White, Garret M. Hampton, John R. Walker, Steven C. L. Ho, Andreas Krause, Dean B. Evans et al. · 2007 · The Journal of Steroid Biochemistry and Molecular Biology
  81. The Prevention and Management of Distant Metastases in Women with Breast Cancer
    Stefan Glück · 2007 · Cancer Investigation
  82. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
    Dieter Koeberle, Beat Thuerlimann · 2007 · Breast Cancer Research and Treatment
  83. Aromatase Inhibitors and Inactivators for Breast Cancer Therapy
    Per Eystein Lønning · 2002 · Drugs & Aging
  84. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial
    Alain Monnier · 2006 · Expert Review of Anticancer Therapy
  85. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients
    Theodora Kunovac Kallak, J. Baumgart, Anneli C. Stavreus-Evers, Inger Sundström Poromaa, Lena Moby, Kristiina Kask, Ensio Norjavaara, Mark M. Kushnir, Jonas Bergquist, K. Nilsson · 2012 · Climacteric
  86. Predicting response and resistance to endocrine therapy
    William R. Miller, Alexey A. Larionov, Thomas James Anderson, John R. Walker, Andreas Krause, Dean B. Evans, J. Michael Dixon · 2007 · Cancer
  87. A Comparison of the Efficacy of Aromatase Inhibitors in Second-Line Treatment of Metastatic Breast Cancer
    Carsten Rose · 2003 · American Journal of Clinical Oncology
  88. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition
    Anne Kendall, Mitch Dowsett · 2006 · Endocrine Related Cancer
  89. Recommandations pour la pratique clinique de Saint-Paul-de-Vence
    Mo�se Namer, Joseph Gligorov, É. Luporsi, D. Serin, Fabrice André, Patricia de Crémoux, Philippe J. M. Chollet, Krishna B. Clough, Jean‐Marc Guinebretière, Emmanuel Achille et al. · 2005
  90. Aromatase Inhibition in Obese Women: How Much Is Enough?
    Jennifer A. Ligibel, Eric P. Winer · 2012 · Journal of Clinical Oncology
  91. Skeletal Manifestations of Treatment of Breast Cancer
    Palak U. Choksi, Margaret Williams, Patricia M. Clark, Catherine H. Van Poznak · 2013 · Current Osteoporosis Reports
  92. A decade of letrozole: FACE
    Joyce O’Shaughnessy · 2007 · Breast Cancer Research and Treatment
  93. Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis
    Song Yao, Yali Zhang, Li Tang, Janise M. Roh, Cecile A. Laurent, Chi‐Chen Hong, Theresa Hahn, Joan Chia-Mei Lo, Christine B. Ambrosone, Lawrence H. Kushi et al. · 2016 · Breast Cancer Research and Treatment
  94. Aromatase inhibitors: prediction of response and nature of resistance
    William R. Miller · 2010 · Expert Opinion on Pharmacotherapy
  95. Discovery of novel aromatase inhibitors using a homogeneous time-resolved fluorescence assay
    Jin‐Zi Ji, Kejing Lao, Jie Hu, Tao Pang, Zhenzhou Jiang, Haoliang Yuan, Jingshan Miao, Xin Chen, Shan-shan Ning, Hua Xiang et al. · 2014 · Acta Pharmacologica Sinica
  96. Aromatase Inhibitors for the Treatment and Prevention of Breast Cancer
    Mamta Kalidas, Powel H. Brown · 2005 · Clinical Breast Cancer
  97. Adjuvant Endocrine Treatment of Early Breast Cancer
    Per Eystein Lønning · 2007 · Hematology/Oncology Clinics of North America
  98. Aromatase Inhibitor–Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer
    Raju Khatri, Preeti Shah, Rupa Guha, Feyruz Virgilia Rassool, Alan E. Tomkinson, Angela M. H. Brodie, Anil K. Jaiswal · 2015 · Molecular Cancer Therapeutics · Retracted
  99. Indications and limitations of third-generation aromatase inhibitors
    Per Eystein Lønning, Jürgen Geisler · 2008 · Expert Opinion on Investigational Drugs
  100. The role of androgens in experimental rodent mammary carcinogenesis
    Jaesung Peter Choi, Basil Psarommatis, Yan Gao, Yu Zheng, David J. Handelsman, Ulla Simanainen · 2014 · Breast Cancer Research